HC Wainwright & Co. Maintains Buy on Poseida Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reaffirmed a Buy rating on Poseida Therapeutics (NASDAQ:PSTX) and increased the price target from $15 to $20. This adjustment reflects a positive outlook on the company's prospects.
December 11, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics' stock may see a positive short term impact due to HC Wainwright & Co.'s maintained Buy rating and increased price target from $15 to $20.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by HC Wainwright & Co. suggests a strong conviction in Poseida Therapeutics' growth potential, which could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100